

software) (personal communication, Apex Corp, August 1995) and time-consuming to use. The single, most common source of nonadherence has been shown to be forgetfulness.²⁴ Based on the most frequently occurring problems associated with nonadherence, common strategies such as information and motivation have been used. However, it is unclear what strategies work best to enhance adherence.²⁴

Accepted for publication October 4, 1995.

This research was supported by the following grants: CN-25429 from the National Cancer Institute, Bethesda, Md; EDT-55 from the American Cancer Society, Atlanta, Ga; MO1-RR00042 from The John Munn Fund of the University of Michigan Cancer Center and National Institutes of Health, General Clinical Research Center, Bethesda, Md; and by the Veterans Affairs, Ann Arbor, Mich.

Reprint requests to 300 Simpson Memorial Bldg, 102 Observatory St, Ann Arbor, MI 48109-0724 (Dr Brenner).

REFERENCES

1. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? *Clin Pharmacol Ther.* 1989;46:163-168.
2. Zelen M. Are primary cancer trials feasible? *J Natl Cancer Inst.* 1988;80:1442-1444.
3. Arnold AM, Browman GP, Johnstone B, Skingley P, Booker L, Levine MN. Chemoprevention for lung cancer: evidence for a high degree of compliance. *Cancer Detect Prev.* 1990;5:521-525.
4. Berenson M, Goshen S, Miller H, Decosse J. Subject-reported compliance in a chemoprevention trial for familial adenomatous polyposis. *J Behav Med.* 1989;12:233-247.
5. Urquhart J. Noncompliance: the ultimate absorption barrier. In: Prescott LF, Nimmo WS, eds. *Novel Drug Delivery and Its Therapeutic Application.* New York, NY: John Wiley & Sons Inc; 1989:127-137.
6. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Oulette V. How often is medication taken as prescribed? a novel assessment technique. *JAMA.* 1989;261:3273-3277.
7. Lebovits AH, Strain JJ, Schleifer SJ, Tanaka JS, Bhardwaj S, Messe MR. Patient noncompliance with self-administered chemotherapy. *Cancer.* 1990;65:17-22.
8. Rudd P, Byyny RL, Zachary V, et al. The natural history of medication compliance in a drug trial of pill counts. *Clin Pharm Ther.* 1989;46:170-176.
9. Waterhouse DM, Calzone KA, Mele C, Brenner, D. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. *J Clin Oncol.* 1993;2:1189-1197.
10. Love RR. Prospects for antiestrogen chemoprevention of breast cancer. *J Natl Cancer Inst.* 1990;82:18-21.
11. Fischer B, Constantino J, Redmond C. A randomized trial evaluation of tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-positive tumors. *N Engl J Med.* 1989;320:479-484.
12. Cramer JA, Mattson RH. Monitoring compliance with antiepileptic drug therapy. In: Cramer JA, Spilker B, eds. *Patient Compliance in Medical Practice and Clinical Trials.* New York, NY: Raven Press; 1991:123-137.
13. Maenpaa H, Javela K, Pikkarainen J, Malkonen M, Heinonen OP, Manninen V. Minimal doses of digoxin: a new marker for compliance to medication. *Eur Heart J.* 1987;8(suppl 1):31-37.
14. Maenpaa H, Manninen V, Heinonen OP. Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial. *Eur Heart J.* 1987;8(suppl 1):39-43.
15. Black DM, Brand RJ, Greenlick M, Hughes G, Smith J. Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. *J Gerontol.* 1987;42:552-557.
16. Sackett DL. Hypertension in the real world: public reaction, physician response, and patient compliance. In: Genest J, Koiv E, Kuchel O, eds. *Hypertension: Physiopathology and Treatment.* New York, NY: McGraw-Hill International Inc; 1977:1142-1149.
17. Greenberg ER, Baron JA, Freeman D Jr, Mandel JS, Haile R. Reduced risk of large-bowel adenomas among aspirin users: the polyp prevention study group. *J Natl Cancer Inst.* 1983;11:912-916.
18. Paganini-Hill A, Chao A, Ross R, Henderson B. Aspirin use and chronic disease: a cohort study of elderly. *BMJ.* 1989;6710:127-150.
19. Paganini-Hill A, Hsu G, Ross RK, Henderson BE. Aspirin use and reduced risk of fatal colon cancer. *N Engl J Med.* 1992;19:1290-1291.
20. Paganini-Hill A. Aspirin and the prevention of colorectal cancer: a review of the evidence. *Semin Surg Oncol.* 1994;3:158-164.
21. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. *J Natl Cancer Inst.* 1993;15:1220-1224.
22. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. *Ann Intern Med.* 1994;4:241-246.
23. Glynn RJ, Buring JE, Manson JE, LaMotte F, Hennekens CH. Adherence to aspirin in the prevention of myocardial infarction: a physicians' health study. *Arch Intern Med.* 1994;154:2649-2657.
24. Cramer JA. Identifying and improving compliance patterns: a composite plan for health care providers. In: Cramer JA, Spilker B, eds. *Patient Compliance in Medical Practice and Clinical Trials.* New York, NY: Raven Press; 1991:387-392.

Announcement

Free Patient Record Forms Available

Patient record forms are available free of charge to ARCHIVES readers by calling or writing FORMEDIC, 12D Worlds Fair Dr, Somerset, NJ 08873-9863, telephone (908) 469-7031.